Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put ANI Pharmaceuticals, Inc. (ANIP - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, ANI Pharmaceuticals has a trailing twelve months PE ratio of 17.7, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 21.4. If we focus on the stock’s long-term PE trend, the current level puts ANI Pharmaceuticals’ current PE ratio below its midpoint over the past three years.
Further, the stock’s PE also compares favorably with the industry’s trailing twelve months PE ratio, which stands at 34.6. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that ANI Pharmaceuticals has a forward PE ratio (price relative to this year’s earnings) of 11.3, so it is fair to say that a slightly more value-oriented path may be ahead for the stock in the near term too.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, ANI Pharmaceuticals has a P/S ratio of 4.1. This is higher than the S&P 500 average, which comes in at 3.4 right now. ANI Pharmaceuticals is overvalued compared to peers from this perspective.
Broad Value Outlook
In aggregate, ANI Pharmaceuticals currently has a Zacks Value Style Score of B, putting it into the top 20% of all stocks we cover from this look. This makes ANI Pharmaceuticals a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the P/CF ratio (another great indicator of value) comes in at 10.5, is better than the industry average of 22.4. Clearly, ANIP is a good choice on the value front from multiple angles.
What About the Stock Overall?
Though ANI Pharmaceuticals might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of A and a Momentum score of A. This gives ANIP a Zacks VGM score—or its overarching fundamental grade—of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been encouraging. The consensus estimate for the current quarter has moved north by 7.2% while that of the current year has increased by 18.6% in the past two months. You can see the consensus estimate trend and recent price action for the stock in the chart below:
ANI Pharmaceuticals, Inc. Price and Consensus
Even though ANI Pharmaceuticals has a better estimates trend, the stock has just a Zacks Rank #3 (Hold). That is why we are looking for in-line performance from the company in the near term.
ANI Pharmaceuticals is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (bottom 25%), it is hard to get too excited about this company overall. Also, over the past year, the industry has underperformed the broader market, as you can see below:
So, value investors might want to wait for the broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks’ has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks. >>